BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 21147532)

  • 1. Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core.
    Shen DM; Brady EJ; Candelore MR; Dallas-Yang Q; Ding VD; Feeney WP; Jiang G; McCann ME; Mock S; Qureshi SA; Saperstein R; Shen X; Tong X; Tota LM; Wright MJ; Yang X; Zheng S; Chapman KT; Zhang BB; Tata JR; Parmee ER
    Bioorg Med Chem Lett; 2011 Jan; 21(1):76-81. PubMed ID: 21147532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists.
    Shen DM; Zhang F; Brady EJ; Candelore MR; Dallas-Yang Q; Ding VD; Dragovic J; Feeney WP; Jiang G; McCann PE; Mock S; Qureshi SA; Saperstein R; Shen X; Tamvakopoulos C; Tong X; Tota LM; Wright MJ; Yang X; Zheng S; Chapman KT; Zhang BB; Tata JR; Parmee ER
    Bioorg Med Chem Lett; 2005 Oct; 15(20):4564-9. PubMed ID: 16102966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of potent, orally active benzimidazole glucagon receptor antagonists.
    Kim RM; Chang J; Lins AR; Brady E; Candelore MR; Dallas-Yang Q; Ding V; Dragovic J; Iliff S; Jiang G; Mock S; Qureshi S; Saperstein R; Szalkowski D; Tamvakopoulos C; Tota L; Wright M; Yang X; Tata JR; Chapman K; Zhang BB; Parmee ER
    Bioorg Med Chem Lett; 2008 Jul; 18(13):3701-5. PubMed ID: 18539028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of cyclic guanidines as potent, orally active, human glucagon receptor antagonists.
    Sinz C; Chang J; Lins AR; Brady E; Candelore M; Dallas-Yang Q; Ding V; Jiang G; Lin Z; Mock S; Qureshi S; Salituro G; Saperstein R; Shang J; Szalkowski D; Tota L; Vincent S; Wright M; Xu S; Yang X; Zhang B; Tata J; Kim R; Parmee E
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7131-6. PubMed ID: 22001094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of N-aryl-2-acylindole human glucagon receptor antagonists.
    Sinz C; Bittner A; Brady E; Candelore M; Dallas-Yang Q; Ding V; Jiang G; Lin Z; Qureshi S; Salituro G; Saperstein R; Shang J; Szalkowski D; Tota L; Vincent S; Wright M; Xu S; Yang X; Zhang B; Tata J; Kim R; Parmee ER
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7124-30. PubMed ID: 22030028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds.
    Shen DM; Shu M; Willoughby CA; Shah S; Lynch CL; Hale JJ; Mills SG; Chapman KT; Malkowitz L; Springer MS; Gould SL; DeMartino JA; Siciliano SJ; Lyons K; Pivnichny JV; Kwei GY; Carella A; Carver G; Holmes K; Schleif WA; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller MD; Emini EA
    Bioorg Med Chem Lett; 2004 Feb; 14(4):941-5. PubMed ID: 15012998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part 1: Structure-activity relationship studies of 5-alkylamino pyrazoles and discovery of a potent, selective, and orally active analog.
    Sakya SM; DeMello KM; Minich ML; Rast B; Shavnya A; Rafka RJ; Koss DA; Cheng H; Li J; Jaynes BH; Ziegler CB; Mann DW; Petras CF; Seibel SB; Silvia AM; George DM; Lund LA; St Denis S; Hickman A; Haven ML; Lynch MP
    Bioorg Med Chem Lett; 2006 Jan; 16(2):288-92. PubMed ID: 16275075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity.
    Filipski KJ; Bian J; Ebner DC; Lee EC; Li JC; Sammons MF; Wright SW; Stevens BD; Didiuk MT; Tu M; Perreault C; Brown J; Atkinson K; Tan B; Salatto CT; Litchfield J; Pfefferkorn JA; Guzman-Perez A
    Bioorg Med Chem Lett; 2012 Jan; 22(1):415-20. PubMed ID: 22119466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New beta-alanine derivatives are orally available glucagon receptor antagonists.
    Lau J; Behrens C; Sidelmann UG; Knudsen LB; Lundt B; Sams C; Ynddal L; Brand CL; Pridal L; Ling A; Kiel D; Plewe M; Shi S; Madsen P
    J Med Chem; 2007 Jan; 50(1):113-28. PubMed ID: 17201415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists.
    Dallas-Yang Q; Shen X; Strowski M; Brady E; Saperstein R; Gibson RE; Szalkowski D; Qureshi SA; Candelore MR; Fenyk-Melody JE; Parmee ER; Zhang BB; Jiang G
    Eur J Pharmacol; 2004 Oct; 501(1-3):225-34. PubMed ID: 15464082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes.
    Xiong Y; Guo J; Candelore MR; Liang R; Miller C; Dallas-Yang Q; Jiang G; McCann PE; Qureshi SA; Tong X; Xu SS; Shang J; Vincent SH; Tota LM; Wright MJ; Yang X; Zhang BB; Tata JR; Parmee ER
    J Med Chem; 2012 Jul; 55(13):6137-48. PubMed ID: 22708876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of conformationally constrained tri-substituted ureas as potent antagonists of the human glucagon receptor.
    Liang R; Abrardo L; Brady EJ; Candelore MR; Ding V; Saperstein R; Tota LM; Wright M; Mock S; Tamvakopolous C; Tong S; Zheng S; Zhang BB; Tata JR; Parmee ER
    Bioorg Med Chem Lett; 2007 Feb; 17(3):587-92. PubMed ID: 17126016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human glucagon receptor antagonists with thiazole cores. A novel series with superior pharmacokinetic properties.
    Madsen P; Kodra JT; Behrens C; Nishimura E; Jeppesen CB; Pridal L; Andersen B; Knudsen LB; Valcarce-Aspegren C; Guldbrandt M; Christensen IT; Jørgensen AS; Ynddal L; Brand CL; Bagger MA; Lau J
    J Med Chem; 2009 May; 52(9):2989-3000. PubMed ID: 19385613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The discovery of N-((2H-tetrazol-5-yl)methyl)-4-((R)-1-((5r,8R)-8-(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822): a potent and selective glucagon receptor antagonist.
    DeMong D; Dai X; Hwa J; Miller M; Lin SI; Kang L; Stamford A; Greenlee W; Yu W; Wong M; Lavey B; Kozlowski J; Zhou G; Yang DY; Patel B; Soriano A; Zhai Y; Sondey C; Zhang H; Lachowicz J; Grotz D; Cox K; Morrison R; Andreani T; Cao Y; Liang M; Meng T; McNamara P; Wong J; Bradley P; Feng KI; Belani J; Chen P; Dai P; Gauuan J; Lin P; Zhao H
    J Med Chem; 2014 Mar; 57(6):2601-10. PubMed ID: 24527772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458).
    Liu L; Siegmund A; Xi N; Kaplan-Lefko P; Rex K; Chen A; Lin J; Moriguchi J; Berry L; Huang L; Teffera Y; Yang Y; Zhang Y; Bellon SF; Lee M; Shimanovich R; Bak A; Dominguez C; Norman MH; Harmange JC; Dussault I; Kim TS
    J Med Chem; 2008 Jul; 51(13):3688-91. PubMed ID: 18553959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, structure-activity relationships, and docking studies of pyrazole-containing derivatives as a novel series of potent glucagon receptor antagonists.
    Shu S; Cai X; Li J; Feng Y; Dai A; Wang J; Yang D; Wang MW; Liu H
    Bioorg Med Chem; 2016 Jun; 24(12):2852-63. PubMed ID: 27161876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel series of indazole-/indole-based glucagon receptor antagonists.
    Lin S; Zhang F; Jiang G; Qureshi SA; Yang X; Chicchi GG; Tota L; Bansal A; Brady E; Trujillo M; Salituro G; Miller C; Tata JR; Zhang BB; Parmee ER
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4143-7. PubMed ID: 26303893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of furan-2-carbohydrazides as orally active glucagon receptor antagonists.
    Hasegawa F; Niidome K; Migihashi C; Murata M; Negoro T; Matsumoto T; Kato K; Fujii A
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4266-70. PubMed ID: 25127101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.
    Xue CB; Wang A; Meloni D; Zhang K; Kong L; Feng H; Glenn J; Huang T; Zhang Y; Cao G; Anand R; Zheng C; Xia M; Han Q; Robinson DJ; Storace L; Shao L; Li M; Brodmerkel CM; Covington M; Scherle P; Diamond S; Yeleswaram S; Vaddi K; Newton R; Hollis G; Friedman S; Metcalf B
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7473-8. PubMed ID: 21036044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The discovery of novel cyclohexylamide CCR2 antagonists.
    Lanter JC; Markotan TP; Zhang X; Subasinghe N; Kang FA; Hou C; Singer M; Opas E; McKenney S; Crysler C; Johnson D; Molloy CJ; Sui Z
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7496-501. PubMed ID: 22061641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.